Tai Sandi See
Chief Development Officer · Lexeo Therapeutics, Inc.
- 2025
- Nov 20, 2025
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Tai Sandi See files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Richard Nolan Townsend - $656K in LXEO purchases and sales in the last 12 months
- Narinder Pal Bhalla - $99K in LXEO purchases and sales in the last 12 months
- Jose Manuel Otero - $79K in LXEO purchases and sales in the last 12 months
- Louis Edward Tamayo - $41K in LXEO purchases and sales in the last 12 months
- Jenny Robertson - $37K in LXEO purchases and sales in the last 12 months
- Eric Adler - $36K in LXEO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Tai Sandi See?
Tai Sandi See is a corporate insider, tracked as Chief Development Officer of Lexeo Therapeutics, Inc. (LXEO). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Tai Sandi See last file a Form 4?
The most recent primary Form 4 on record is dated 20 November 2025, one of 3 filings going back to 2025.
Has Tai Sandi See been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($40K) across all tracked filings.
